Anıl Yıldız (Anıl Yildiz)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Epidermal Growth Factor Receptor

Patient Reported Outcomes

Ejection Fraction

Top Venues

Turkish journal of medical sciences

Medicina (Kaunas, Lithuania)

This page only lists publications with an associated author ORCID identifier.

Publications

Oguzcan Kinikoglu, Hatice Odabaş, Yunus Emre Altıntaş, Anıl Yıldız, Burçin Çakan, Goncagül Akdağ, Sedat Yildirim, Hamit Bal, Tuğba Kaya, Salih Tünbekici, Deniz Işık, Tuğba Başoğlu, Mahmut Emre Yildirim, Nedim Turan
Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Medicina (Kaunas, Lithuania) 60 (6) (2024)
Oguzcan Kinikoglu, Hatice Odabaş, Yunus Emre Altıntaş, Anıl Yıldız, Burçin Çakan, Goncagül Akdağ, Sedat Yildirim, Hamit Bal, Tuğba Kaya, Salih Tünbekici, Deniz Işık, Tuğba Başoğlu, Mahmut Emre Yildirim, Nedim Turan
Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Medicina (Kaunas, Lithuania) 60 (6) (2024)
Naziye Ak, Zeynep Tuz, Esra Aydin, Ferhat Ferhatoglu, Murat Sarı, Nail Paksoy, Izzet Dogan, Anıl Yıldız, Rian Dişçi, Pınar Mualla Saip
The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients. Turkish journal of medical sciences 54 (1) (2023)
Naziye Ak, Zeynep Tuz, Esra Aydin, Ferhat Ferhatoglu, Murat Sarı, Nail Paksoy, Izzet Dogan, Anıl Yıldız, Rian Dişçi, Pınar Mualla Saip
The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients. Turkish journal of medical sciences 54 (1) (2023)